PLx Pharma Inc
F:1D5A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PLx Pharma Inc
Free Cash Flow
PLx Pharma Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
PLx Pharma Inc
F:1D5A
|
Free Cash Flow
-$59.3m
|
CAGR 3-Years
-73%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Free Cash Flow
$19.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Free Cash Flow
$12.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
26%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Free Cash Flow
$9.1B
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Free Cash Flow
$12.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
16%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Free Cash Flow
$6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
16%
|
|
PLx Pharma Inc
Glance View
PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. The company is headquartered in Sparta, New Jersey and currently employs 16 full-time employees. The company went IPO on 2014-03-13. The firm has two commercialized products, VAZALORE 81 milligram (mg) and VAZALORE 325 mg, which are liquid-filled aspirin capsules for over the counter (OTC) distribution. The firm markets VAZALORE to the healthcare professional and the consumer through several sales and marketing channels. Its product pipeline also includes other oral NSAIDs using the PLxGuard drug delivery platform, including PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, for pain and inflammation in Phase I clinical stage. PLxGuard drug delivery platform employs a pH-dependent release mechanism that relies on association of lipidic excipients with APIs for targeted release in the GI tract.
See Also
What is PLx Pharma Inc's Free Cash Flow?
Free Cash Flow
-59.3m
USD
Based on the financial report for Sep 30, 2022, PLx Pharma Inc's Free Cash Flow amounts to -59.3m USD.
What is PLx Pharma Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-49%
Over the last year, the Free Cash Flow growth was -179%. The average annual Free Cash Flow growth rates for PLx Pharma Inc have been -73% over the past three years , -49% over the past five years .
